CT-guided iodine-125 brachytherapy as salvage therapy for local-regional recurrent breast cancer.
brachytherapy
breast cancer
computed tomography guidance
iodine-125 seed
recurrence
salvage therapy
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
03
04
2023
accepted:
06
07
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
The treatment of local-regional recurrent breast cancer (BC) after external beam radiotherapy is challenging. We aim to evaluate the effectiveness and safety of computed tomography (CT)-guided percutaneous iodine-125 brachytherapy for local recurrent BC. We retrospectively analyzed 15 patients with local recurrent BC treated with CT-guided interstitial implantation of iodine-125 seeds. Regular contrast-enhanced CT was conducted to evaluate the tumor response. Follow-up survival, quality of life, and adverse events were analyzed. Among the 15 patients, five were elderly patients (older than 80 years) and six were complicated with chronic underlying diseases. The median number of CT-guided iodine-125 brachytherapy provided a safe and effective choice for recurrent BC with significant local therapeutic effects and minor complications, especially for elderly patients with chronic underlying disease and those who were not eligible for surgical resection and had failed to benefit from systemic therapy.
Sections du résumé
Background
UNASSIGNED
The treatment of local-regional recurrent breast cancer (BC) after external beam radiotherapy is challenging. We aim to evaluate the effectiveness and safety of computed tomography (CT)-guided percutaneous iodine-125 brachytherapy for local recurrent BC.
Methods
UNASSIGNED
We retrospectively analyzed 15 patients with local recurrent BC treated with CT-guided interstitial implantation of iodine-125 seeds. Regular contrast-enhanced CT was conducted to evaluate the tumor response. Follow-up survival, quality of life, and adverse events were analyzed.
Results
UNASSIGNED
Among the 15 patients, five were elderly patients (older than 80 years) and six were complicated with chronic underlying diseases. The median number of
Conclusions
UNASSIGNED
CT-guided iodine-125 brachytherapy provided a safe and effective choice for recurrent BC with significant local therapeutic effects and minor complications, especially for elderly patients with chronic underlying disease and those who were not eligible for surgical resection and had failed to benefit from systemic therapy.
Identifiants
pubmed: 37664064
doi: 10.3389/fonc.2023.1171813
pmc: PMC10471796
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1171813Informations de copyright
Copyright © 2023 Wang, Chang, Xu, Liang, Zhao, Liu and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Gynecol Oncol. 2021 Mar;32(2):e50
pubmed: 33650344
World J Surg Oncol. 2020 Nov 25;18(1):307
pubmed: 33239023
Front Oncol. 2021 Feb 10;10:600525
pubmed: 33643906
Cancers (Basel). 2022 May 23;14(10):
pubmed: 35626168
Front Oncol. 2022 Aug 01;12:884491
pubmed: 35978802
BMC Cancer. 2020 Jun 24;20(1):591
pubmed: 32580723
Ann Surg Oncol. 2013 Oct;20(11):3430-7
pubmed: 23720073
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Prostate Cancer Prostatic Dis. 2004;7(3):201-7
pubmed: 15184864
Pathol Oncol Res. 2019 Jan;25(1):327-332
pubmed: 29116622
Comput Intell Neurosci. 2022 May 4;2022:6257536
pubmed: 35571719
Cancers (Basel). 2014 Nov 27;6(4):2343-55
pubmed: 25437254
Chin Med J (Engl). 2022 Feb 9;135(5):584-590
pubmed: 35143424
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819825845
pubmed: 30803402
J Contemp Brachytherapy. 2020 Dec;12(6):579-585
pubmed: 33437306
Cancer Biother Radiopharm. 2019 Nov;34(9):547-550
pubmed: 31524501
Oncotarget. 2017 Mar 4;8(35):59766-59776
pubmed: 28938680
J Interv Med. 2021 Feb 27;4(2):82-86
pubmed: 34805953
Radiat Oncol. 2018 Feb 03;13(1):18
pubmed: 29394937
JAMA Oncol. 2016 Aug 1;2(8):1075-82
pubmed: 27243924
Cancer Biol Ther. 2019;20(2):212-218
pubmed: 30296196
J Natl Cancer Inst. 2005 Jan 19;97(2):116-26
pubmed: 15657341
Front Oncol. 2022 Feb 15;12:773708
pubmed: 35242700
Eur J Cancer. 2005 Nov;41(17):2637-44
pubmed: 16115758
Front Oncol. 2021 Sep 30;11:717180
pubmed: 34660280
J Cancer Res Ther. 2018;14(7):1660-1664
pubmed: 30589056
J Contemp Brachytherapy. 2021 Jun;13(3):347-357
pubmed: 34122576